InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
0
T+90 hit rate
42%
T+90 mean return
+9.4%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by McClain Sean, Chief Executive Officer. Director active across 1 company, notably Absci Corp. Aggregated, 16 disclosures have been logged. Breakdown: 4 buys · 0 sell. Total volume traded: €104k. History available since 26 July 2021. The latest transaction was filed on 2 March 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations16 total
59,896 sharesCommon StockSEC:0001672688-26-000121:0
406,200 shares0Common StockSEC:0001672688-26-000051:0
406,200 shares0Common StockSEC:0001672688-26-000051
26,761 shares@ US$2.9928.3% of flowCommon StockSEC:0001672688-26-000027
26,761 shares@ US$2.990.013% mcap28.3% of flowCommon StockSEC:0001672688-26-000027:0
23,293 shares@ US$3.6817.3% of flowCommon StockSEC:0001672688-25-000071:0
190,200 shares0Common StockSEC:0001672688-25-000017:0
16,991 shares@ US$3.7114.2% of flowCommon StockSEC:0001672688-25-000008:0
14,543 shares@ US$4.0712.7% of flowCommon StockSEC:0001672688-24-000042:0
1,500,000 shares0Common StockSEC:0001672688-24-000018:0
182,000 shares0Common StockSEC:0001672688-24-000011:0
175,000 shares0Common StockSEC:0001672688-23-000033:0
7,155 shares@ US$6.9210.2% of flowCommon StockSEC:0001628280-22-001083
Canonical exit: 19 Apr 2022 (T+90)
7,155 shares@ US$6.920.0083% mcap18.3% of flowCommon StockSEC:0001628280-22-001083:0
Canonical exit: 19 Apr 2022 (T+90)
600 shares@ US$16.001.9% of flowCommon StockSEC:0001628280-21-014738
Canonical exit: 24 Oct 2021 (T+90)
600 shares@ US$16.000.0015% mcap3.4% of flowCommon StockSEC:0001628280-21-014738:0
Canonical exit: 24 Oct 2021 (T+90)
16 of 16 declarations
About McClain Sean
Sean McClain is the Chief Executive Officer and President of Absci Corp. He is responsible for the strategic direction of the company and the management of daily operations. His leadership is essential in achieving the financial and operational objectives of the company in the biopharmaceutical sector.
